QQQ   387.29 (+0.25%)
AAPL   193.42 (+2.11%)
MSFT   372.52 (+0.92%)
META   318.29 (-0.54%)
GOOGL   130.99 (+1.33%)
AMZN   146.88 (+1.41%)
TSLA   238.72 (+1.33%)
NVDA   465.66 (+2.33%)
NIO   7.43 (+1.37%)
BABA   72.39 (-0.88%)
AMD   118.38 (-0.16%)
T   17.22 (+3.36%)
F   10.60 (-0.93%)
MU   73.69 (-0.81%)
CGC   0.67 (-11.90%)
GE   120.24 (-1.06%)
DIS   90.80 (-1.32%)
AMC   7.03 (-6.15%)
PFE   29.09 (-0.65%)
PYPL   57.92 (-3.22%)
XOM   100.44 (-1.94%)
QQQ   387.29 (+0.25%)
AAPL   193.42 (+2.11%)
MSFT   372.52 (+0.92%)
META   318.29 (-0.54%)
GOOGL   130.99 (+1.33%)
AMZN   146.88 (+1.41%)
TSLA   238.72 (+1.33%)
NVDA   465.66 (+2.33%)
NIO   7.43 (+1.37%)
BABA   72.39 (-0.88%)
AMD   118.38 (-0.16%)
T   17.22 (+3.36%)
F   10.60 (-0.93%)
MU   73.69 (-0.81%)
CGC   0.67 (-11.90%)
GE   120.24 (-1.06%)
DIS   90.80 (-1.32%)
AMC   7.03 (-6.15%)
PFE   29.09 (-0.65%)
PYPL   57.92 (-3.22%)
XOM   100.44 (-1.94%)
QQQ   387.29 (+0.25%)
AAPL   193.42 (+2.11%)
MSFT   372.52 (+0.92%)
META   318.29 (-0.54%)
GOOGL   130.99 (+1.33%)
AMZN   146.88 (+1.41%)
TSLA   238.72 (+1.33%)
NVDA   465.66 (+2.33%)
NIO   7.43 (+1.37%)
BABA   72.39 (-0.88%)
AMD   118.38 (-0.16%)
T   17.22 (+3.36%)
F   10.60 (-0.93%)
MU   73.69 (-0.81%)
CGC   0.67 (-11.90%)
GE   120.24 (-1.06%)
DIS   90.80 (-1.32%)
AMC   7.03 (-6.15%)
PFE   29.09 (-0.65%)
PYPL   57.92 (-3.22%)
XOM   100.44 (-1.94%)
QQQ   387.29 (+0.25%)
AAPL   193.42 (+2.11%)
MSFT   372.52 (+0.92%)
META   318.29 (-0.54%)
GOOGL   130.99 (+1.33%)
AMZN   146.88 (+1.41%)
TSLA   238.72 (+1.33%)
NVDA   465.66 (+2.33%)
NIO   7.43 (+1.37%)
BABA   72.39 (-0.88%)
AMD   118.38 (-0.16%)
T   17.22 (+3.36%)
F   10.60 (-0.93%)
MU   73.69 (-0.81%)
CGC   0.67 (-11.90%)
GE   120.24 (-1.06%)
DIS   90.80 (-1.32%)
AMC   7.03 (-6.15%)
PFE   29.09 (-0.65%)
PYPL   57.92 (-3.22%)
XOM   100.44 (-1.94%)

Franklin Genomic Advancements ETF (HELX) Price, Holdings, & News

$27.86
-0.29 (-1.03%)
(As of 12/5/2023 ET)
Compare
Today's Range
$27.86
▼
$27.86
50-Day Range
$25.36
▼
$28.48
52-Week Range
N/A
Volume
347 shs
Average Volume
N/A
Market Capitalization
$9.75 million
Assets Under Management
$11.26 million
Dividend Yield
N/A
Net Expense Ratio
0.50%
Stock AnalysisChartHeadlinesHoldingsOwnershipRatings

About Franklin Genomic Advancements ETF

The Franklin Genomic Advancements ETF (HELX) is an exchange-traded fund that is based on the Solactive Genomics index. The fund is an actively managed portfolio of global equity securities of companies relevant to genomic discovery. HELX was launched on Feb 25, 2020 and is managed by Franklin Templeton.

HELX Stock Price History

HELX ETF News Headlines

November 25, 2023 | lse.co.uk
Franklin Msci China Paris Alig Ucits Etf Share Price (FRCP.MI)
November 17, 2023 | lse.co.uk
Franklin Emerging Markets Ucits Etf Share Price (FLXE.MI)
December 5, 2023 | Autonomix (Ad)
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
February 25, 2023 | morningstar.com
BMO ARK Genomic Revolution ETF Series
See More Headlines
Receive HELX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Franklin Genomic Advancements ETF and its competitors with MarketBeat's FREE daily newsletter.

Fund Details

Issuer
Franklin Templeton Investments
Fund Name
Franklin Genomic Advancements ETF
Tax Classification
Regulated Investment Company
Stock Exchange
BATS
Current Symbol
BATS:HELX
Inception Date
2/25/2020
Fund Manager
Matthew J.Moberg, Joyce Lin
Web
N/A
Phone
N/A

Fund Focus

Asset Class
Equity
Benchmark
N/A
Category
Strategy
Focus
Theme
Development Level
Blended Development
Region
Global
Number of Holdings
60

Fund Statistics

Assets Under Management
$11.26 million
Average Daily Volume
$0.00
Discount/Premium
0.00%

Administrator, Advisor and Custodian

Administrator
Franklin Templeton Services, LLC
Advisor
Franklin Advisers, Inc.
Custodian
State Street Bank and Trust Company
Distributor
Franklin Templeton Distributors, Inc.
Transfer Agent
State Street Bank and Trust Company
Trustee
N/A
Lead Market Maker
Citadel

Miscellaneous

Outstanding Shares
350,000
Beta
1.02
Creation Unit
50,000
Creation Fee
$200.00
5G Stocks: The Path Forward is Profitable Cover
5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Franklin Genomic Advancements ETF Expenses

TypeHELXTheme ETFsEquity ETFsBATS ETFsAll ETFs
Management Fee0.50%0.57%0.53%0.55%0.50%
Other Expenses0.00%0.76%0.53%0.51%0.57%
Total Expense0.50%0.73%0.69%0.68%0.69%
Fee Waiver0.00%-0.78%-0.54%-0.36%-0.58%
Net Expense0.50%0.60%0.59%0.62%0.57%

Franklin Genomic Advancements ETF (HELX) Holdings & Exposure

Top 10 HELX Holdings

HELX Sector Exposure

HELX Industry Exposure

Full Holdings Details














HELX ETF - Frequently Asked Questions

How have HELX shares performed in 2023?

Franklin Genomic Advancements ETF's stock was trading at $30.1272 at the start of the year. Since then, HELX shares have decreased by 7.5% and is now trading at $27.86.
View the best growth stocks for 2023 here.

What does HELX invest in?

Franklin Genomic Advancements ETF is a equity fund issued by Franklin Templeton Investments. HELX focuses on theme investments. The fund's investments total to approximately $11.26 million assets under management.

What stocks does Franklin Genomic Advancements ETF hold?

HELX invests in 60 holdings. Some of the stocks in their portfolio include Thermo Fisher Scientific (TMO), Danaher (DHR), Repligen (RGEN), Medpace (MEDP), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Krystal Biotech (KRYS), Corteva (CTVA), AstraZeneca (AZN) and Bruker (BRKR).

What is the management fee for Franklin Genomic Advancements ETF?

Franklin Genomic Advancements ETF's management fee is 0.50% and has no other recorded expenses or fee waivers. The net expense ratio for HELX is 0.50%.

Who are Franklin Genomic Advancements ETF's major shareholders?

Franklin Genomic Advancements ETF's stock is owned by many different institutional and retail investors. Top institutional shareholders include LPL Financial LLC (2.61%).

How do I buy shares of Franklin Genomic Advancements ETF?

Shares of HELX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (BATS:HELX) was last updated on 12/5/2023 by MarketBeat.com Staff

My Account -